Your idea isn't totally out of reality.
If you take a look at LI KA SHING's biotech company HUTCHMED's pipeline targets (below):
- Gastric Cancer
- NSCLC
- Breast Cancer
Might as well license something that targets HER-2 receptors, with the possibility of also expanding into TIGIT, LAG3 etc.
Take a 10% equity stake in the company while they're at it.
Then buy out the entire company once the oncolytic virus and oncarlytics show their safety after a Phase I.
Ann: Annual Report to shareholders, page-46
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.8¢ |
Change
0.002(3.57%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 5.7¢ | 5.9¢ | 5.6¢ | $448.0K | 7.718M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 549100 | 5.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.9¢ | 1097920 | 17 |
View Market Depth
| Last trade - 12.52pm 23/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |